

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/25256 A2

- (51) International Patent Classification⁷: C07K
Circle of Hope, Salt Lake City, UT 84112 (US). MANOS, Elizabeth [US/US]; Huntsman Cancer Institute, Room 5262, 2000 Circle of Hope, Salt Lake city, UT 84112 (US).
- (21) International Application Number: PCT/US00/27868
- (22) International Filing Date: 6 October 2000 (06.10.2000) (74) Agent: GIDDINGS, Barton; Madson & Metcalf, Suite 900, 15 West South Temple, Salt Lake City, UT 84101 (US).
- (25) Filing Language: English
- (26) Publication Language: English (81) Designated States (national): CA, JP, US.
- (30) Priority Data: 60/157,913 6 October 1999 (06.10.1999) US (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (71) Applicant (for all designated States except US): UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US]; Technology Transfer Office, Suite 110, 612 Arapeen drive, Salt Lake City, UT 84108 (US). Published:
— Without international search report and to be republished upon receipt of that report.
- (72) Inventors; and
(75) Inventors/Applicants (for US only): JONES, David [US/US]; Huntsman Cancer Institute, Room 5262, 2000

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRDL-1-GAMMA, A NOVEL TUMOR NECROSIS-LIKE LIGAND

```
1 MPASSPFLAPKGGPPGNMGGPVREPALSVALWLSWG TRDL-1α
1 MPASSPFLAPKGGPPGNMGGPVREPALSVALWLSWG TRDL-1β
1 MPASSPFLAPKGGPPGNMGGPVREPALSVALWLSWG TRDL-1γ

37 AALGAVACAMALLTQQTELOSLRREVSRLQGTGGPS TRDL-1α
37 AALGAVACAMALLTQQTELOSLRREVSRLQGTGGPS TRDL-1β
37 AALGAVACAMALLTQQTELOSLRREVSRLQGTGGPS TRDL-1γ

73 QNGEGYPWQSLPEQSSDALEAWENGERSRKRAVLT TRDL-1α
73 QNGEGYPWQSLPEQSSDALEAWENGERSRKRAVLT TRDL-1β
73 QNGEGYPWQSLPEQSSDALEAWENGERSRKRAVLT TRDL-1γ

109 QKQKKQHSLVHLVPIINATSKDDSDVTEVMWQPALRR TRDL-1α
109 QKQKL-----NDSDVTEVMWQPALRR TRDL-1β
109 QKQKKQHSLVHLVPIINATSKDDSDVTEVMWQPALRR TRDL-1γ

145 GRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQ TRDL-1α
129 GRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQ TRDL-1β
145 GRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQ TRDL-1γ

181 VVSREGQGRQETLFRCI RSMPSHPDRAYNSCY SAGV TRDL-1α
165 VVSREGQGRQETLFRCI RSMPSHPDRAYNSCY SAGV TRDL-1β
181 VVSREGQGRQETLFRCI RSMPSHPDRAYNSCY SAGV TRDL-1γ

217 FHLHQGDILSVIIPRARA KLNLS PHGTFLGFVKL TRDL-1α
201 FHLHQGDILSVIIPRARA KLNLS PHGTFLGFVKL TRDL-1β
217 FHLHQGDILSVIIPRARA KLNLS PHGTFLG--L TRDL-1γ
```

(57) Abstract: The present invention relates to a novel human alternatively spliced Tumor Necrosis-Like Ligand (TRDL) (SEQ ID NO:2). Nucleic acid molecules that encode for the novel TRDL-1γ have been identified and purified. The sequence of such a nucleic acid molecule can be found at SEQ ID NO:1. Provided herein are nucleic acid molecules that encode such TRDL molecules. The present invention also provides recombinant vectors comprising nucleic acid molecules that code for TRDL-1γ. In certain embodiments, these recombinant vectors are plasmids. In certain embodiments, these recombinant vectors are prokaryotic or eukaryotic expression vectors. In certain especially preferred embodiments, the nucleic acid coding for TRDL-1γ is operably linked to a heterologous promoter. The present invention further provides host cells comprising a nucleic acid that codes for TRDL-1γ. TRDL-1 has been shown to stimulate Jurkat cell death. Moreover, TRDL-1 binds to existing members of the TNF receptor family including, FAS and HVEM. Examination of 48 tumor samples revealed high levels of TRDL-1 expression in several tumors including those from the gastrointestinal tract.

WO 01/25256 A2